Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission

Journal of Hepatology

Volumn 58, Issue 1, 2013, Pages 141-147

  Van Gerven, Nicole M F ^a   Verwer, Bart J ^a   Witte, Birgit I ^a   Van Hoek, Bart ^b   Coenraad, Minneke J ^b   Van Erpecum, Karel J ^c   Beuers, Ulrich ^d   Van Buuren, Henk R ^e   De Man, Rob A ^e   Drenth, Joost P H ^f   Den Ouden, Jannie W ^g   Verdonk, Robert C ^h   Koek, Ger H ⁱ   Brouwer, Johannes T ^j   Guichelaar, Maureen M J ^k   Mulder, Chris J J ^a   Van Nieuwkerk, Karin M J ^a   Bouma, Gerd ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g HAGA HOSPITAL   (Netherlands)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j REINIER DE GRAAF HOSPITAL   (Netherlands)

^k MEDISCH SPECTRUM TWENTE   (Netherlands)

more..

Author keywords

Autoimmune hepatitis; Azathioprine; Drug withdrawal; Medication; Relapse; Remission; Steroids

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; CHILD; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; REMISSION; RETREATMENT; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AZATHIOPRINE; CHILD; FEMALE; FOLLOW-UP STUDIES; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 84871211618     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.09.009     Document Type: Article

References (22)

1. K.M. Boberg Prevalence and epidemiology of autoimmune hepatitis Clin Liver Dis 6 2002 635 647
2. I.G. McFarlane The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis Gut 42 1998 599 602
3. M. Werner, H. Prytz, B. Ohlsson, S. Almer, E. Bjornsson, and A. Bergquist Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study Scand J Gastroenterol 43 2008 1232 1240
4. M.P. Manns, A.J. Czaja, J.D. Gorham, E.L. Krawitt, G. Mieli-Vergani, and D. Vergani Diagnosis and management of autoimmune hepatitis Hepatology 51 2010 2193 2213
5. F. Alvarez, P.A. Berg, F.B. Bianchi, L. Bianchi, A.K. Burroughs, and E.L. Cancado International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis J Hepatol 31 1999 929 938
6. M.M. Lamers, M.G. van Oijen, M. Pronk, and J.P. Drenth Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials J Hepatol 53 2010 191 198
7. W.H. Summerskill, M.G. Korman, H.V. Ammon, and A.H. Baggenstoss Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared Gut 16 1975 876 883
8. A.J. Czaja Drug therapy in the management of type 1 autoimmune hepatitis Drugs 57 1999 49 68
9. R.D. Soloway, W.H. Summerskill, A.H. Baggenstoss, M.G. Geall, G.L. Gitnick, and I.R. Elveback Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis Gastroenterology 63 1972 820 833
10. A.J. Czaja, H.V. Ammon, and W.H. Summerskill Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission Gastroenterology 78 1980 518 523
11. J.E. Hegarty, K.T. Nouri Aria, B. Portmann, A.L. Eddleston, and R. Williams Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis Hepatology 3 1983 685 689
12. A.J. Czaja, K.V. Menon, and H.A. Carpenter Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis Hepatology 35 2002 890 897
13. A.J. Czaja, J. Ludwig, A.H. Baggenstoss, and A. Wolf Corticosteroid- treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis N Engl J Med 304 1981 5 9
14. A.J. Czaja, G.L. Davis, J. Ludwig, and H.F. Taswell Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis Hepatology 4 1984 622 627
15. B. Jharap, M.L. Seinen, N.K. de Boer, G. Van Jr., R.K. Linskens, and J.C. Kneppelhout Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts Inflamm Bowel Dis 16 2010 1541 1549
16. L. Peyrin-Biroulet, K. Khosrotehrani, F. Carrat, A.M. Bouvier, J.B. Chevaux, and T. Simon Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease Gastroenterology 141 2011 1621 1628
17. M.A. Smith, P.M. Irving, A.M. Marinaki, and J.D. Sanderson Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease Aliment Pharmacol Ther 32 2010 119 130
18. A.J. Czaja, A.M. Wolf, and A.H. Baggenstoss Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features Gastroenterology 80 1981 687 692
19. S. Luth, J. Herkel, S. Kanzler, C. Frenzel, P.R. Galle, and H.P. Dienes Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis J Clin Gastroenterol 42 2008 926 930
20. A.J. Montano-Loza, H.A. Carpenter, and A.J. Czaja Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse Am J Gastroenterol 102 2007 1005 1012
21. A.J. Montano-Loza, H.A. Carpenter, and A.J. Czaja Consequences of treatment withdrawal in type 1 autoimmune hepatitis Liver Int 27 2007 507 515
22. A.J. Czaja Treatment of autoimmune hepatitis Semin Liver Dis 22 2002 365 378